Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular ...

Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low ...

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

Dyne has aligned with the U.S. Food and Drug Administration (FDA) on the HARMONIA Phase 3 trial design and protocol. HARMONIA is intended to serve as a confirmatory trial to support conversion of ...
The Brighterside of News on MSN

Breakthrough intramuscular injection speeds heart attack recovery

For a heart just damaged by a blocked artery, timing matters. So does access. That is what makes a new experimental treatment ...

Arcturus Therapeutics Balances Pipeline Progress With Cash Strain

Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.